Market Pathways
✓

Market Pathways

MENGENAI PODCAST INI 🔗

Your premium guide to global medical device regulation, reimbursement and policy. Market Pathways delivers incomparable intelligence exploring the people, challenges, and opportunities impacting the global medtech regulatory and reimbursement community. View the latest issue of Market Pathways on MyStrategist.com
Kesihatan & Kecergasan
Ubat-ubatan
Ubat-ubatan
Hos:
Kekerapan kemas kini:
every 92 days
Purata panjang audio:
44 minutes
Temu bual tetamu
Bahasa Inggeris
Amerika Syarikat
35 episod
sejak 1 Jul 2021
episodic
GunakanAPIuntuk mengambil podcast ini dalamJSON

DI DALAM PODCAST INI 🔗

Edit tag ini

EPISOD TERKINI 🔗

Ep. 35: MDR: Is Real Change on the Horizon?

Ep. 35: MDR: Is Real Change on the Horizon?

The need for important changes to MDR has been clear since its enactment in 2017. EU authorities have been reluctant to make substantive revisions, content to do nothing more than extend regulatory timelines. Now, however, there seems to be newfound resolve in Brussels to engage in fundamental r ...
00:52:44
KONGSI
SIMPAN

CARI EPISOD LEPAS

Cari episod lepas bagi Market Pathways.
Masukkan bar carian ini ke laman web anda

EPISOD SEBELUMNYA

Ep. 34: What I Learned From 25 Years at CMS: An Interview With Tamara Syrek Jensen

Ep. 34: What I Learned From 25 Years at CMS: An Interview With Tamara Syrek Jensen

After a long career at CMS, including running the Coverage and Analysis Group for the past 10 years, Tamara Syrek Jensen can now candidly share her views on medical device reimbursement generally, particularly when it comes to Medicare. She provides a frank assessment on the systemic challenges, ...
00:45:40
KONGSI
SIMPAN
Ep. 33: What Does it Mean to be a Reimbursement Professional?

Ep. 33: What Does it Mean to be a Reimbursement Professional?

Veteran medtech reimbursement executive Keely Scamperle talks about her newly launched Reimbursement and Market Access Professional Society, or RAMPSociety. She discusses the growth of reimbursement and market access as a distinct profession over her career and how she hopes the new group will h ...
00:32:37
KONGSI
SIMPAN
Ep. 32: The Tariff Challenge, Policy Optimism, and The MedTech Conference With Scott Whitaker

Ep. 32: The Tariff Challenge, Policy Optimism, and The MedTech Conference With Scott Whitaker

Scott Whitaker, president and CEO of AdvaMed, sits down with Market Pathways’ David Filmore to talk about hot topics in medtech policy, including the current situation with tariffs, future optimism for policies coming out of FDA and CMS, a Breakthrough Device coverage bill moving in Congress, Ad ...
00:45:37
KONGSI
SIMPAN
EP 31: Haven’t We Heard This Song Before? Major EU Regulatory Changes on the Horizon

EP 31: Haven’t We Heard This Song Before? Major EU Regulatory Changes on the Horizon

A special panel from our Innovation Summit Dublin conference in April 2025 Pedro Eerdmans, MD, PhD, Director, Global Strategy Services at NAMSA Tom Melvin, Associate Professor in Medical Device Regulatory Science, Institute for Clinical Trials, University of Galway; Chair, Biomedical Alliance i ...
00:44:20
KONGSI
SIMPAN
BTIG Weighs In on Whether Trump Policies Can Dent MedTech’s Healthy Run

BTIG Weighs In on Whether Trump Policies Can Dent MedTech’s Healthy Run

By Wendy DillerFollowing a robust 2024, the medical device sector continues to thrive in 2025 and remains somewhat insulated from dramatic shifts in healthcare policies, at least in the short term. Market Pathways and MedTech Strategist writer Wendy Diller spoke on March 3, 2025 with Ryan Zimmer ...
00:29:54
KONGSI
SIMPAN
Pioneering the Use of Real-World Evidence in Medtech: A Discussion with J&J’s Paul Coplan

Pioneering the Use of Real-World Evidence in Medtech: A Discussion with J&J’s Paul Coplan

The use of real-world evidence is increasing rapidly throughout the device industry. Here we talk with Paul Coplan, who is leading that effort at J&J, which received the first FDA-approved label extension using real-world evidence. Our conversation embraces the breadth of real-world evidence ...
01:06:17
KONGSI
SIMPAN
FDA Inspections Getting Prepped and Avoiding Pitfalls

FDA Inspections Getting Prepped and Avoiding Pitfalls

FDA inspections are nobody’s idea of a good time. However, proper planning is crucial not only for ensuring baseline compliance, but also for establishing an effective corporate culture and building long-term company value. In this edition of Consultants Corner, we spotlight  advice from Jamie H ...
00:31:44
KONGSI
SIMPAN
A VC’s View of the Reimbursement Evolution: An Interview with Mike Carusi

A VC’s View of the Reimbursement Evolution: An Interview with Mike Carusi

Reimbursement has gone from being largely ignored to becoming top of mind for both product companies and investors. Mike Carusi was among the early proponents of understanding and improving the coding, coverage and payment processes. Here he takes us through the reimbursement evolution and delve ...
00:49:25
KONGSI
SIMPAN
Reimbursement for Breakthrough Devices Still Lags—Need for TCET: An Interview with Josh Makower

Reimbursement for Breakthrough Devices Still Lags—Need for TCET: An Interview with Josh Makower

This discussion with Stanford Biodesign director and co-founder Josh Makower highlights a recent Stanford report that found the median time for initial coverage of breakthrough devices was nearly six years. Here we discuss how this data, much like information from previous Stanford reports, can ...
00:56:25
KONGSI
SIMPAN
Penafian: Podcast dan karya seni yang dibenamkan pada halaman ini adalah daripada Market Pathways, yang merupakan hak milik pemiliknya dan tidak bergabung dengan atau disokong oleh Listen Notes, Inc.
ENJIN PENCARIAN PODCAST
Anda boleh menggunakan tapak web kami untuk mencari podcast3,834,224dan episod197,217,619mengikut orang, tempat atau topik.
Pelaburan dalam ilmu memberikan pulangan terbaik, jadi saya mendengar podcast.  ‐ Benjamin "Llamacorn" Franklin

SARANAN

Gunakan API untuk mendapatkan podcast ini